CD19 and diffuse large B-cell lymphoma: Derlin et al. analyzed ten patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma with Tisagenlecleucel, an autologous CD19 CAR-T-cell product, using serial [18F]FDG PET/CT scans.